Celcuity Reports After Analysts Raised Targets But Before ASCO Presents the Data

Celcuity Inc (CELC) reports first-quarter 2026 earnings after the close on May 14, with analysts expecting a loss of $1.07 per share. The central question for investors: can this clinical-stage biotechnology company continue its pattern of beating estimates while advancing its pipeline of targeted cancer therapies? With the stock trading near recent highs and analyst sentiment strengthening, the market is watching closely for updates on clinical trial progress and cash runway.

Part 1: Earnings Preview

Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for cancer patients based on key cellular signaling pathways. The company's lead programs target HER2-positive and hormone receptor-positive breast cancers, with a proprietary diagnostic platform designed to identify patients most likely to respond to its therapies.

Celcuity will report Q1 2026 results after the market close on Wednesday, May 14, with the consensus calling for a loss of $1.07 per share. The company most recently reported a loss of $0.97 per share for Q4 2025, beating the estimate of $1.06 by $0.09. Year-over-year, the expected loss of $1.07 represents a 24.42% wider loss compared to the $0.86 loss reported in Q1 2025, reflecting increased investment in clinical development.

Three key themes define this earnings story heading into the release:

Clinical Trial Momentum: Investors are focused on enrollment progress and any interim data readouts from Celcuity's ongoing Phase 3 trials. Updates on patient recruitment rates and trial timelines will be critical for validating the company's development pathway and commercial timeline expectations.

Cash Runway and Financing Strategy: With operating losses expected to continue through 2026, the market is watching the company's cash position and burn rate closely. Any commentary on financing plans or strategic partnerships could significantly impact investor confidence in the company's ability to fund operations through key clinical milestones.

Regulatory Pathway Clarity: As Celcuity advances its lead programs, investors are seeking greater visibility into the regulatory strategy and potential approval timelines. Management's guidance on interactions with the FDA and plans for regulatory submissions will be closely scrutinized.

Analyst commentary ahead of the release has been notably bullish, with 11 of 13 analysts rating the stock a Strong Buy. Recent upgrades reflect growing confidence in the company's clinical data and commercial potential, with price targets ranging from $125 to $189. Analysts are particularly focused on the company's ability to differentiate its therapies in a competitive oncology landscape and establish a clear path to commercialization.

Part 2: Historical Earnings Performance

Celcuity has demonstrated a consistent pattern of beating earnings estimates over the past four quarters, with positive surprises in three of the last four reports. The company beat estimates by 9.47% in Q1 2025, missed by 15.56% in Q2 2025, then delivered back-to-back beats of 12.38% in Q3 2025 and 8.49% in Q4 2025.

The trend shows improving execution, with the company reporting losses of $0.86, $1.04, $0.92, and $0.97 over the past four quarters against estimates of $0.95, $0.90, $1.05, and $1.06 respectively. The Q2 miss appears to be an outlier in an otherwise positive track record, as Celcuity has generally managed operating expenses more efficiently than analysts anticipated. This pattern of modest but consistent beats suggests management has maintained disciplined cost control while advancing its clinical programs, though the year-over-year increase in expected losses reflects the natural progression of higher clinical trial costs as programs mature.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Celcuity typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action shows significant volatility around Celcuity's earnings releases, with an average absolute Day 0 move of 3.34% and Day +1 move of 4.10%. The most recent earnings on March 25, 2026 produced the strongest reaction in the dataset, with an 8.05% Day 0 gain followed by a 4.16% Day +1 advance, reflecting strong investor enthusiasm for the Q4 results.

The pattern reveals considerable variability in post-earnings behavior. While the two most recent reports (March 2026 and November 2025) generated substantial gains of 8.05% and 7.56% respectively on Day 0, earlier reports in 2024 and early 2025 showed more muted or negative reactions. The Day +1 ranges averaging 12.22% indicate that follow-through volatility can be substantial, suggesting investors should prepare for potential swings in either direction as the market digests the results and management commentary.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 4.71% through the May 15 expiration, which sits between the historical Day 0 average of 3.34% and the Day +1 average of 4.10%. This suggests options traders are anticipating a reaction roughly in line with recent historical patterns, though notably below the 8.05% Day 0 move from the most recent March earnings.

Part 3: What Analysts Are Saying

Analysts maintain a strongly bullish stance on Celcuity, with the consensus rating at 4.77 out of 5.00 — firmly in Strong Buy territory. The current breakdown shows 11 Strong Buys, 1 Moderate Buy, and 1 Hold, with no sell ratings. Sentiment has improved over the past month, with two analysts upgrading from Hold to Strong Buy, pushing the rating higher from 4.58.

The average price target of $154.09 implies 23.8% upside from the current price of $124.47, with the range of targets spanning from $125.00 to $189.00. The high-end target of $189 suggests some analysts see potential for more than 50% appreciation if clinical milestones are achieved and the company successfully advances its pipeline. This widening range of targets reflects both the significant opportunity analysts see in Celcuity's platform and the inherent uncertainty in clinical-stage biotechnology investing, where binary outcomes from trial data can dramatically shift valuations.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a Buy signal at 88%, down from 100% Buy readings both last week and last month, indicating some recent softening in technical momentum despite the longer-term uptrend remaining intact.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal suggests near-term momentum has cooled from recent highs, with the stock consolidating after its strong run
• Medium-term (100% Buy): Strong buy signal indicates solid intermediate-term momentum remains firmly positive
• Long-term (100% Buy): Strong buy signal reflects powerful longer-term trend strength as the stock has more than doubled from its 52-week low

Trend Characteristics: The trend shows Average strength with the Weakest directional reading, suggesting the stock is in a mature uptrend that may be losing some momentum heading into earnings.

The stock is trading at $124.47, positioned below its 5-day ($127.31), 10-day ($130.97), and 20-day ($126.26) moving averages, indicating recent short-term weakness. However, the price remains above its 50-day ($118.81), 100-day ($112.65), and 200-day ($89.48) moving averages, confirming the broader uptrend remains intact. This setup suggests the stock has pulled back from recent highs near $130 and is consolidating ahead of earnings, with the 50-day average potentially serving as support.

Key technical levels to watch include the 20-day moving average at $126.26 as immediate resistance and the 50-day at $118.81 as support. The stock's position below its short-term averages but well above longer-term trend lines creates a neutral-to-slightly-cautious technical setup heading into earnings. A strong beat could propel the stock back above $130 toward the $151 52-week high, while a disappointment might test support in the $118-$120 zone where the 50-day average resides.